Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bristol Myers Squibb Q3 2026 Results: Net Income $2.16B, Down 1.8% YoY

Bristol-Myers Squibb reported total revenues of $13.1 billion for the third quarter of 2026, a 7% increase compared to the prior year. Net earnings attributable to BMS remained stable at $2.2 billion for the quarter, while nine-month net earnings grew significantly from $6.0 billion in 2025 to $8.2 billion in 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue13,069.012,222.0
Profit before tax2,536.03,114.0
Net income2,162.02,201.0
EPS (diluted, $ a share)$1.05$1.08

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-1.8%
Revenue, year on year+6.9%
Source

10-Q filed with the SEC, NYSE: BMY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bristol Myers Squibb Co: key numbers

Share price
$62.93Close, Nov 16
Market cap
$129B
Shares outstanding
2.04BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bristol Myers Squibb Co

All →
4:26 PM ET Form 4
Insider Selling

Bristol Myers Squibb Insider Julia A. Haller Sells $241K of Stock

Julia A. Haller sold 3,800 shares of Bristol Myers Squibb Co at $63.31 a share, worth $241K in total on Nov 5, 2026. Shares held after the trade: 30,279 (-11.2%).

Value
$241K
Shares
3,800
Price
$63.31
Holding change
-11.2%
Trade date
Nov 5, 2026
7:06 AM ET 8-K
Financial Results

Bristol Myers Squibb Financial Results

Bristol Myers Squibb reported third quarter 2026 revenues of $13.1 billion, a 7% increase driven by double-digit growth in its Growth Portfolio. The company raised its full-year 2026 revenue guidance to a range of $49.75 billion to $50.25 billion following strong performance from key products like Opdivo Qvantig and Reblozyl.

Term
Q3 2026

“We delivered another quarter of double-digit growth in our Growth Portfolio, which increased 12% and reflects the continued momentum across our diversified portfolio. The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones. As we look forward to additional late-stage data in the near term, we remain focused on executing with discipline, investing where we see the greatest opportunity and strengthening the foundation for sustainable growth.”

Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.